• Search
  • Helpdesk
  • Sales contact
Get your demo

Article

Patient-Reported Outcomes in early-phase oncology clinical trials
A Stepping Stone to a Patient-Centered Drug Development

Oncology
In phase I clinical trials, the recommended phase II dose (RP2D) is usually set at or near the maximum tolerated dose (MTD), which is determined based on the observation of...

Answering the Sustainability Call: Digital Health Technologies and eCOA

CSR
With over 350,000 registered clinical trials worldwide, the research industry contributes an estimated 27.5 million tons of CO₂ equivalent, highlighting...

Empowering patients through education – A structured approach to clinical trial engagement

Patient engagement
In the evolving landscape of clinical research, patient engagement has emerged as a cornerstone of successful clinical trials. In addition...

Expanding investor confidence: The strategic value of Patient Reported Outcomes (PROs) in biotech fundraising

biotechfundraisingPRO
For biotech companies engaged in the clinical development of a therapeutic innovation, securing investor trust is as critical as demonstrating...

Leveraging the potential of Patient Reported Outcome (PRO) data to accelerate therapeutic innovation market access

biotechmarket accessPRO
Patients Reported Outcome (PRO) data provide information on patient health that is obtained directly from the patient.PRO measures serve to...

Turning experience into evidence: PROs in IBD clinical research

Gastroenterology
Inflammatory Bowel Disease (IBD), including Crohn’s disease or Ulcerative Colitis, presents a complex and highly individualized clinical picture, making it...

Strategies to promote BYOD adoption by clinical study sites

BYOD
Bring Your Own Device (BYOD) approaches have been increasingly adopted in recent years, and the multiple advantages they bring to...

If Patients Want A Better Quality Of Life, Why Isn’t That A Focus For Pharma?

OncologyPatient engagement
A conversation with Frédéric Fiteni, Ph.D., medical oncologist and oncology PRO specialist, University Hospital of Nîmes, and, member of Kayentis Scientific...

Data Collection in Clinical Trials with Multiple Caregivers

In clinical trials, especially those involving participants unable to self-report—such as children or individuals with cognitive impairments—caregiver-reported data is essential....

Kayentis 2024 Gender Equality Index

CSR
In accordance with the provisions of the French "Professional Future" law of September 5, 2018, Kayentis has established its Gender...

Client satisfaction at its best: Kayentis achieves 90%+ client recommendation rate 4 years in a row

At Kayentis, we’re pleased to share the results of our latest client survey, conducted in January 2025. The feedback highlights...

The unquestionable value of electronic Clinical Outcome Assessments (eCOA) in rheumatoid arthritis clinical research

Immuno-Inflammation
Rheumatoid Arthritis (RA) is a common, chronic disease that causes inflammation and often presents with pain in the joints. Untreated,...

Ensure successful outcomes with strong patient collaboration at every stage of your clinical trial

Patient engagement
Patients, who live with their conditions daily, have invaluable insights that make them essential partners in developing effective treatments and...

Empowering healing: The impact of patient partnerships in clinical trials

Patient engagement
The landscape of clinical trials has evolved significantly over recent decades, moving from a purely scientific focus to a more...

Collecting PRO data in leukemia clinical research: the only way to meaningfully improve patients’ quality of life

Oncology
The prevalence of leukemia is increasing worldwide. Chronic Myeloid Leukemia (CML) patients benefit from recently improved care but receive prolonged,...

Collecting PRO data in cancer trials: bringing the patient perspective in oncology clinical research

Oncology
As one of the biggest research area, oncology remains the focus of the clinical trials pipeline, comprising 44% of the...

Rare disease clinical research: it is time to tackle what matters most to patients

Rare disease
Supporting the development and evaluation of new treatments for rare diseases has become a key priority of the 21st century....

The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

MetabolicScientific advice
NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally and is the most severe...

The relevance of ePROs in early phase clinical trials

Scientific advice
Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the investigational product in humans, finding...

3 considerations to take into account when setting up an eCOA clinical trial

Televisit
In a clinical trials environment that is moving increasingly towards digitalization and decentralization, it remains crucial to maintain high-quality electronic...

Addressing challenges with eCOA at the site-level

eCOA consortium
The eCOA: Getting Better Together Initiative launched by the Critical Path Institute in 2019 aimed to identify and address issues...

Flexible approaches to eCOA administration in clinical trials: The site perspective

eCOA consortium
To address the need to embed flexibility in eCOA use, the “Support Flexible Approaches to PRO Data Collection” project was...

4 key points to consider when implementing a study with caregiver assessments

Patient engagement
The level of support provided by caregivers during clinical trials can be very variable. This can range from providing emotional...

Implementing electronic Patient Reported Outcomes (ePROs) in Arthritis Clinical Research: Importance, benefits, and management for incorporating ePROs

Immuno-Inflammation
Arthritis is a general term categorized by acute or chronic inflammation of the joints. Arthritis may cause a variety of...

Direct insights from cancer patients: How they help us understand disease burden and the need for an individualized approach

OncologyPatients insights
Cultural differences and individual preferences have a significant impact on healthcare and clinical trial experience. Solutions exist in attempt to...

The shift to data collection at home: Strategies to support flexibility, ensure data quality, and preserve data privacy

Scientific advice
The rate at which we now collect data in clinical trials is astonishing. With decentralization of clinical trials, study data...

Kayentis Media Player, for informed and engaged patients in clinical trials

Patient engagement
Patients taking part in clinical trials need clear and simple information – this is what 70% of 1,133 survey participants...

Giving voice to study patients via the Participant Feedback Questionnaire

Patient engagement
Increasing the engagement of study patients can be done in multiple ways: one way to do it is to ask...

Mitigating the risks of long-term oncology eCOA clinical trials

Oncology
Long study duration can have a negative impact on patient complianceAs for any clinical trial, poor compliance in oncology studies...

Televisits in clinical trials: Why integrate a telemedecine feature in your eCOA solution?

Televisit
With clinical trials digitalization and decentralization comes the possibility for patients to complete several of their clinical study procedures remotely,...

Addressing the specific complexities of oncology eCOA clinical trials

Oncology
The oncology research pathway is paved with numerous challenges, and oncology clinical trials have one of the lowest success rates....

DCT trials

Decentralized trials
The added value of a single platform DCT trials means bringing the study to the patient’s environment instead of asking...

Expanding flexibility of eCOA data collection with controlled interview mode

Patient engagement
With quickly evolving technologies, electronic Patient Reported Outcomes (ePROs) can now be administered in a variety of ways. If ePRO...

Key considerations for the implementation of successful Decentralized Clinical Trials (DCTs)

Decentralized trials
Many chronic diseases such as invasive cancers, inflammatory disorders, cardiovascular, or central nervous system diseases can have a significant impact...

3 good reasons to adopt Decentralized Clinical Trials (DCT)

Decentralized trials
The clinical trials industry has been facing numerous and long-lasting challenges of patient recruitment and retention, patient compliance, and clinical...

Paving the way towards carbon neutral eCOA trials

CSR
COVID-19 caused businesses to adopt new practices, including moving many operations online and leading to a positive impact on CO2...

Clinical trials digitalization: why it helps clinical trials stakeholders

The decline in R&D efficiency is one of the biggest challenges the pharmaceutical industry is facing today. The development of...
Default Image

How can digital innovation turn clinical trials into a positive patient and site experience?

Digital innovation is increasingly penetrating the healthcare industry and technological advances create a new avenue for the optimization of clinical...

Data Management – Essential for all studies including eCOA

Data management
  In a perfect world, you would choose your Clinical Outcome Assessments (COAs), write your statistical analysis plan (SAP), license...

WebCOA back-up
The best balance for data quality, ease-of-use, and cost for your clinical studies!

webcoa
7 reasons to choose a web-based back-up solution for your eCOA studies   WebCOA is a back-up solution, which is...

eCOA solutions in oncology: how to avoid common pitfalls and ensure the success of long-term studies?

Oncology
Among numerous clinical study procedures, capturing patients reported outcomes can bring its own set of challenges and, if not well...

Partnering with patients to boost clinical research in rare diseases

Patients insightsRare disease
Although much progress has been made in developing scientific knowledge and conducting clinical research in rare diseases, serious challenges remain....

eCOA Training: how can we improve the sites’ and patients’ experience? #whitepaper

Patient engagementProject management
Focused on eCOA training, this white paper transcribes the discussion from one in a series of 4 workshops about eCOA...

eCOA in ophthalmology: The five keys for successful ePRO selection in your ophthalmology clinical trial

Ophthalmology
There is an extended use of Patient Reported Outcome (PRO) measures in clinical trials used to assess health-related quality of...

Overcoming the Complexities of Pediatric Clinical Trials

Pediatric
Although children make up 25% of the world’s population, at least 50% of all drug products may still lack labeling...

Waste Management Report 2018

CSR
Kayentis is committed to responsible waste management After the promotion of environmentally friendly transport - 2018 Sustainable Mobility Report - (e.g....
Follow us on social media
Subscribe to our newsletter
You may also like

ePRO in early phase oncology trials: A revolution on the...

Patient-Reported Outcomes in early-phase oncology clinical trialsA Stepping Stone to...

Answering the Sustainability Call: Digital Health Technologies and eCOA

Kayentis secures Silver Medal in EcoVadis sustainability evaluation with significant...

Engage patients throughout the clinical trial journey

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.